IL259947B - Heteroarylhydroxypyrimidinones as agonists of the apj receptor - Google Patents

Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Info

Publication number
IL259947B
IL259947B IL259947A IL25994718A IL259947B IL 259947 B IL259947 B IL 259947B IL 259947 A IL259947 A IL 259947A IL 25994718 A IL25994718 A IL 25994718A IL 259947 B IL259947 B IL 259947B
Authority
IL
Israel
Prior art keywords
heteroarylhydroxypyrimidinones
receptor agonists
apj receptor
apj
agonists
Prior art date
Application number
IL259947A
Other languages
English (en)
Hebrew (he)
Other versions
IL259947A (en
Inventor
R Michael Lawrence
Michael C Myers
Heather Finlay
Wei Meng
Donna M Bilder
Zulan Pi
Robert Paul Brigance
Original Assignee
Bristol Myers Squibb Co
R Michael Lawrence
Michael C Myers
Heather Finlay
Wei Meng
Donna M Bilder
Zulan Pi
Robert Paul Brigance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, R Michael Lawrence, Michael C Myers, Heather Finlay, Wei Meng, Donna M Bilder, Zulan Pi, Robert Paul Brigance filed Critical Bristol Myers Squibb Co
Publication of IL259947A publication Critical patent/IL259947A/en
Publication of IL259947B publication Critical patent/IL259947B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
IL259947A 2015-12-16 2018-06-11 Heteroarylhydroxypyrimidinones as agonists of the apj receptor IL259947B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16
PCT/US2016/066750 WO2017106396A1 (en) 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Publications (2)

Publication Number Publication Date
IL259947A IL259947A (en) 2018-07-31
IL259947B true IL259947B (en) 2020-10-29

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259947A IL259947B (en) 2015-12-16 2018-06-11 Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Country Status (21)

Country Link
US (1) US10669261B2 (https=)
EP (1) EP3390400B1 (https=)
JP (1) JP6948322B2 (https=)
KR (1) KR102742744B1 (https=)
CN (1) CN108602813B (https=)
AR (1) AR107061A1 (https=)
AU (1) AU2016372048B2 (https=)
BR (1) BR112018012112A2 (https=)
CA (1) CA3008630A1 (https=)
CL (1) CL2018001621A1 (https=)
CO (1) CO2018007221A2 (https=)
EA (1) EA036736B1 (https=)
ES (1) ES2854733T3 (https=)
HK (1) HK1255163A1 (https=)
IL (1) IL259947B (https=)
MX (1) MX380669B (https=)
PE (1) PE20181487A1 (https=)
SG (1) SG11201804674UA (https=)
TW (1) TW201725203A (https=)
UY (1) UY37026A (https=)
WO (1) WO2017106396A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196771A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
WO2017103611A1 (en) 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン
KR102384668B1 (ko) * 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル-マイヤーズ スクイブ カンパニー 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
CZ298812B6 (cs) 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1686119B1 (en) * 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
JP2004504302A (ja) 2000-07-18 2004-02-12 ニューロジェン・コーポレーション 5−置換2−アリール−4−ピリミジノン
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2485148A1 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
MXPA05011387A (es) 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007510652A (ja) 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−4−オン化合物、組成物、および方法
JP2007518711A (ja) 2003-12-19 2007-07-12 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−4−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
PL2079707T3 (pl) 2006-10-10 2015-05-29 Proionic Gmbh Sposób wymiany 1,3-hetero-aromatycznych 2-karboksylanów z wodą
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
EP2279192B1 (en) 2008-05-28 2013-10-30 Merck Patent GmbH Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
EP2715858A1 (en) 2011-05-31 2014-04-09 Merck Patent GmbH Electrolyte formulations
SG195086A1 (en) 2011-05-31 2013-12-30 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统(湖州)有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
RU2015114772A (ru) * 2012-09-21 2016-11-10 Санофи Производные амида бензоимидазол-карбоновой кислоты в качестве модуляторов рецептора apj
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
WO2014078778A2 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
US20170015871A1 (en) 2013-11-29 2017-01-19 Proionic Gmbh Method for curing an adhesive using microwave irradiation
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
WO2015188073A1 (en) * 2014-06-06 2015-12-10 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
WO2016196771A1 (en) * 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
UY37005A (es) 2015-12-04 2017-06-30 Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
KR102384668B1 (ko) 2016-06-14 2022-04-07 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
JP6962941B2 (ja) 2016-06-14 2021-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル-マイヤーズ スクイブ カンパニー 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト

Also Published As

Publication number Publication date
PE20181487A1 (es) 2018-09-18
US10669261B2 (en) 2020-06-02
MX380669B (es) 2025-03-12
EP3390400A1 (en) 2018-10-24
UY37026A (es) 2017-06-30
CL2018001621A1 (es) 2018-08-03
CO2018007221A2 (es) 2018-07-19
CA3008630A1 (en) 2017-06-22
AU2016372048B2 (en) 2021-02-04
JP6948322B2 (ja) 2021-10-13
EA201891336A1 (ru) 2019-01-31
WO2017106396A1 (en) 2017-06-22
CN108602813B (zh) 2021-10-29
CN108602813A (zh) 2018-09-28
AR107061A1 (es) 2018-03-14
IL259947A (en) 2018-07-31
KR20180095577A (ko) 2018-08-27
EA036736B1 (ru) 2020-12-14
JP2018538304A (ja) 2018-12-27
EP3390400B1 (en) 2021-01-20
BR112018012112A2 (pt) 2018-12-04
AU2016372048A1 (en) 2018-08-02
SG11201804674UA (en) 2018-06-28
HK1255163A1 (zh) 2019-08-09
MX2018007155A (es) 2018-08-15
ES2854733T3 (es) 2021-09-22
TW201725203A (zh) 2017-07-16
KR102742744B1 (ko) 2024-12-12
US20180362508A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
DK3368060T3 (da) Glugacon-receptor-agonister
DK3300500T3 (da) Triazolagonister af apj-receptoren
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
PL3151672T3 (pl) Ulepszone kompozycje limfocytów t
DK3130649T3 (da) Haloolefin-baseret sammensætning
PT3157915T (pt) Compostos de dihidroisoquinolinona substituídos
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
FR3024363B1 (fr) Composition thermogelifiable
PL3223827T3 (pl) Kompozycja błonnika pokarmowego
DK3125898T3 (da) Farmakofor til trail-induktion
EP3632350C0 (en) EMBOLIZATION DEVICE
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
CL2017000639A1 (es) Composición
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION
HUE070090T2 (hu) Összetétel
DK3310756T3 (da) Thromboxanreceptorantagonister
DK3280853T3 (da) Holdemekanisme

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed